Amlavetasa: Identity, Traditional Use & What the Evidence Shows

TL;DR

Amlavetasa is a genuinely old Ayurvedic drug, from Charaka's era, usually taken to be Garcinia pedunculata fruit: but it might be several other species, depending on whom you ask. The human evidence is essentially nothing: one case report in a single child. Everything else is lab dishes and animal models. Don't buy it on the name alone.

What it is

Amlavetasa is a classical Ayurvedic amla (sour) drug. It comes with an asterisk that is bigger than the drug itself: the identity is genuinely disputed.

The working identification today, and the one the Ayurvedic pharmacopoeia committee has accepted, is the fruit of Garcinia pedunculata Roxb. ex Buch.-Ham., family Clusiaceae (also cited as Guttiferae): a tall tree of northeastern India (Assam, Manipur) and parts of Myanmar, called "taikor" in Bangladesh (Molecules 2020 review of Garcinia species, PMC). Classically the useful part is the fruit (phala); the leaf (patra) is cited too (Ayurvedic college monograph).

One confusion to clear first: this is not amla. Same first syllable, different drug entirely. Amla is Indian gooseberry, Phyllanthus emblica. I mention it because the names trip up every newcomer, and vendors are not always careful about correcting you.

The identity controversy — read this before buying anything

Here is where I land after reading the monographs: the classical identity of amlavetasa is genuinely up for grabs. An Ayurvedic college monograph lists the candidates in circulation: Rheum emodi (Polygonaceae), Solena heterophylla (Cucurbitaceae), Rumex vesicarius (Polygonaceae), Cissus repens, Cissus vitiginea, Ampelocissus latifolia, and Cayratia trifolia (Vitaceae) (same monograph). That is not a shortlist. That is a confession.

The markets make it worse. Adulteration is documented: dried leaf stalks of Rheum emodi sold as "shakhamla"; branches of Cissus/*Ampelocissus* dipped in citric juice and dried, sold in North Indian markets as "amlavetas." They are not the classical drug. The same IJCRT review that documents this notes the pharmacopoeia committee accepts the lemon-like Thaikal fruit (Garcinia pedunculata) as the real thing (IJCRT critical review).

My take: the name on a packet is not a guarantee of the species inside. If you buy this, ask the supplier for the botanical identity and treat a shrug as an answer.

Traditional use

The classical footprint is real, and I will give it its due. Charaka puts amlavetasa in four groups: Hridya (cardiac tonics), Amla skanda (sour-tasting drugs), Deepaniya (digestives/carminatives), and Shvasahara (drugs for asthma and dyspnea). Sushruta places it in the Amla varga (college monograph).

Bhavaprakasha Nighantu (verses 118–120) goes further. It lists the synonyms: amlavetasa, shukra, shatavedhi ("piercing a hundred ways"), sahasranut, and describes the drug as intensely sour (atyamla), laxative (bhedana), light (laghu), and digestive-stimulant (deepana): useful in heart disease, colic, and gulma (abdominal lumps). Pitta-increasing (pittala); dispelling hiccups, bloating, loss of appetite, asthma, cough, indigestion, and vomiting, while pacifying kapha and vata (Bhavaprakasha Nighantu via e-Nighantu, NIIMH).

The energetics, for the record: sour taste, light/dry/sharp qualities, hot potency, sour post-digestive effect; kapha-vata pacifying but pitta-increasing (college monograph).

All of that is traditional claim. It counts for something. It is not a clinical trial, and I will not let anyone blur the two.

What modern research says

Laboratory and animal studies

Phytochemists have found hydroxycitric acid in the dried fruits, plus the benzophenones garcinol, pedunculol, and isogarcinol (cambogin). Dry-fruit extracts have shown anti-inflammatory, hepatoprotective, cardioprotective, and antioxidant activity in vitro; hexane/chloroform extracts showed antioxidant and antimutagenic activity (Molecules 2020 review, PMC).

That is an honest list of findings. Here is the honest frame: every one of those results is preclinical. Lab dishes and animal models suggest directions for research. They do not tell you what happens in a person. Nobody has bridged that gap for this drug.

Traditionally the fruit has been used for gastrointestinal disorders, as a cardiotonic and emollient, and for asthma, cough, bronchitis, diarrhea, and fever (same review). Traditional use, again. Not a result.

Human evidence: a single case report

The entire human clinical record for amlavetasa is one case study. Published via NIScPR (CSIR): an 8-year-old girl with HbE-β thalassemia received amlavetasa (Garcinia pedunculata) as an adjuvant treatment for 6 months with 2 months of follow-up. The hypothesis was iron chelation. Serum iron and ferritin changes were tracked alongside her transfusion history (case study, NIScPR).

One child. No control. The researchers were testing an idea, not proving a treatment. A case report is hypothesis-generating at best. I would not make a single decision on it.

What the evidence does not support (yet)

There are no randomized trials of amlavetasa for any condition. Zero.

And a warning I consider load-bearing: weight-loss and blood-sugar claims sometimes attached to this name belong to Garcinia cambogia, the source of most hydroxycitric-acid supplement research. They have not been tested for G. pedunculata. Do not transfer one Garcinia's evidence to another. I have seen vendors do exactly this, and it is not honest.

Dosage

I could not verify a pharmacopoeial or trial-based dose for amlavetasa, so I am stating none. Traditional dose figures circulate on blogs and vendor pages without primary citations, and with the identity confusion documented above, repeating them would be irresponsible. A number attached to a contested drug is worse than no number.

Safety & contraindications

Classically amlavetasa is pittala (pitta-increasing), so the traditional caution applies in acid-peptic and pitta-aggravated conditions (college monograph). Beyond that, there are no human safety data. No toxicity trials. No pregnancy or breastfeeding data. No interaction studies. None of the things you would want before putting something in your body.

The biggest practical safety issue is the identity one: material sold as amlavetasa may be a different species entirely. That is not a footnote. It is the main risk.

Pregnant and breastfeeding women, children, and anyone on regular medication should not use it without qualified professional guidance. I would not negotiate with that.

FAQs

What is amlavetasa?

A classical Ayurvedic sour drug, commonly identified today with the fruit of Garcinia pedunculata (family Clusiaceae), a tree of northeastern India. Its exact classical identity is disputed; several other species have been proposed, which is the first thing to understand about it (college monograph).

Is amlavetasa the same as amla?

No. Amla is Indian gooseberry (Phyllanthus emblica). Amlavetasa is a different drug, commonly associated with Garcinia pedunculata. Similar name, different plant, different evidence base.

Is amlavetasa the same as Garcinia cambogia?

No. Different species. Most of the hydroxycitric-acid weight-loss research concerns G. cambogia; it has not been tested for G. pedunculata, so those claims do not transfer (Molecules 2020 review, PMC).

What is amlavetasa used for in Ayurveda?

As a sour digestive and carminative (deepana), a cardiotonic (hridya), and for asthma, cough, colic, bloating, and vomiting, per Charaka's groupings and Bhavaprakasha Nighantu (e-Nighantu). These are traditional uses, not proven effects. I keep the distinction because the tradition deserves respect and the data deserves honesty.

Is there any clinical evidence for amlavetasa?

Only a single case report (an 8-year-old with thalassemia, as an adjuvant) exists; there are no human trials at all (NIScPR case study). Laboratory studies show antioxidant and anti-inflammatory activity in vitro, which is not human proof. Anyone who tells you more than that is extrapolating.

Sources

The phytochemistry and pharmacology picture comes from the Garcinia review in Molecules 2020, section 2.3 on G. pedunculata (PMC7582350): the paper I point anyone to who wants the lab data, with the caveat that everything in it stays preclinical. The identity controversy, classical classification, constituents, and energetics come from the "AMLAVETAS" monograph of Satya Sai Murlidhar Ayurvedic College & Hospital (PDF), a college-level source rather than a peer-reviewed one, and I have read it as such. The classical verse content is Bhavaprakasha Nighantu, Amradi Phalavarga vv. 118–120, via e-Nighantu (NIIMH/CCRAS) (read the text). Market adulteration and the pharmacopoeia committee's acceptance of the Thaikal fruit are documented in the IJCRT critical review, "Secret of Ayurvedic Dravyas as Vital Energy Medicine — Amalvetas" (2023; 11(9)) (PDF), worth reading with the awareness that IJCRT is not a top-tier journal. The single human data point is the NIScPR case study on E-β thalassemia (handle).

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.